Target |
Mechanism Adenosine receptor antagonists |
Active Org.- |
Originator Org. |
Active Indication- |
Inactive Indication |
Drug Highest PhaseWithdrawn |
First Approval Ctry. / Loc. US |
First Approval Date01 Jan 1982 |
Target- |
Mechanism- |
Active Org.- |
Originator Org. |
Active Indication- |
Inactive Indication- |
Drug Highest PhaseWithdrawn |
First Approval Ctry. / Loc. US |
First Approval Date01 Jan 1982 |
Target- |
Mechanism- |
Active Org.- |
Originator Org. |
Active Indication- |
Inactive Indication- |
Drug Highest PhaseWithdrawn |
First Approval Ctry. / Loc. US |
First Approval Date22 Jul 1953 |
Start Date01 May 2023 |
Sponsor / Collaborator |
Start Date19 Dec 2019 |
Sponsor / Collaborator |
Start Date06 Oct 2009 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Dromostanolone Propionate | - | Withdrawn |
Procaine merethoxylline/Theophylline ( Adenosine receptor ) | Dyspnea More | Withdrawn |
Cycrimine Hydrochloride | - | Withdrawn |
LSN-2463359 ( mGluR5 ) | Schizophrenia More | Pending |
NCC-1048 ( calcium channel ) | Perioperative ischaemia More | Pending |